 The figure shows representative images of the CT scans at different times after COVID-19 symptom onset in a 70 year-old woman with adenocarcinoma who had a part of the lung removed and in a 47 year-old man with nasopharyngeal carcinoma.

CT Scans of Cancer Patients 

Cancer patients are immunocompromised and therefore more likely to suffer severe symptoms of COVID-19. It is recommended that cancer patients receiving antitumour treatments in hospitals should be screened for COVID-19 and should attempt to avoid or lower the dosage of treatments causing immunosuppression.

Smith College

Google

The clinical characteristics of 28 patients with severe cases of COVID-19  (in addition to cancer) were retrospectively studied. 

- Patients and Methods
- Results
- Conclusions 

Clinical characteristics of COVID-19-Infected Cancer Patients: Study in Wuhan, China

Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., . . . Zhou, M. (2020). Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Annals of Oncology, 31(7), 894-901. doi:10.1016/j.annonc.2020.03.296
https://www.sciencedirect.com/science/article/pii/S0923753420363833

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

This study included cancer patients with laboratory confirmed SARS-CoV-2 from three hospitals in Wuhan, China. Clinical data were collected from medical records from Jan. 13, to Feb. 26, 2020. Univariate and multivariate analyses were performed to asses the risk factors in regards to severe events (i.e. a condition requiring admission to an intensive care unit, the use of mechanical ventilation, or death). 

Patients and Methods

Out of the 28 patients included in this study, 17 (60.7%) were male. The median age was 65 years, and the most frequent cancer type was lung cancer (25%). The most common clinical features were fever (82.1%), dry cough (81%), dyspnoea (50.0%), and hypoproteinaemia (low level of protein in the blood)(89.3%). More than half of the patients had severe events (53.6%), and the mortality rate was 28.6%. If the last antitumour treatment (cancer treatment) was within the past 14 days, it significantly increased the risk of developing severe events (P = 0.037). 

Learn Before

Related

Learn After